The drug finally was able to pass deliberations by the Review Committee for Cancer Diseases, but still, the company's smile wavers due to the bitter aftertaste left by the committee’s ‘conditional’ approval.

With MSD Korea’s cancer immunotherapy ‘Keytruda (pembrolizumab)’ passing deliberations by the Review Committee for Cancer Diseases in July, industry expectations are rising on the possibility of the drug’s benefit coverage being expanded to first-line in non-small cell lung cancer (NSCLC)

However, under the air of anticipation there lies concerns as the Review Committee for Cancer Diseases had put forward a condition for granting the nod to Keytruda.

During deli